# Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial

> **NCT07732218** · PHASE4 · COMPLETED · sponsor: **Rehman Medical Institute - RMI** · enrollment: 95 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Semaglutide (Ozempic®)

## Key facts

- **NCT ID:** NCT07732218
- **Lead sponsor:** Rehman Medical Institute - RMI
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-04
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732218, "Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*